pairingsPairing
Lecanemab with MRI monitoring
Amyloid antibodies are used with scheduled MRI checks for ARIA, not as a standalone infusion without imaging follow-up.
Overview
This pairing is a teaching node: the medicine and the scan belong together. It is not a local protocol.
Rationale
ARIA monitoring on MRI is part of using an amyloid antibody, not an optional extra.
Evidence
The US lecanemab label requires MRI monitoring for ARIA. See the FDA approval communication.
Similar pages
not linked directly; found by shared links- TechnologyApoE testing
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- CompanyEisai
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- DiagnosisVascular dementia
Shares Brain MRI and the tag dementia-atlas.
- Key paperLecanemab in Early Alzheimer’s Disease (CLARITY AD)
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- CompanyBiogen
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.